TD Cowen reinstated coverage of Evolv (EVLV) with a Buy rating and $10 price target Under new management, the company’s statements have been completed and its regulatory overhangs have “gradually diminished.” the analyst tells investors in a research note. The firm says Evolv reported “healthy” Q2 results and raised its fiscal 2025 revenue outlook as it sees momentum across major verticals.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVLV:
- Evolv Technology Reports Strong Revenue Growth Amid Losses
- Closing Bell Movers: UnitedHealth jumps 10% as Berkshire, Appaloosa buy weakness
- Evolv Technologies Announces Resignation of Chief Innovation Officer
- Evolv reports Q2 adjusted EPS (2c) vs (7c) last year
- Evolv raises FY25 revenue view to $132M-$135M from $125M-$130M